Physician profile
Joseph Fanelli
NPI 1205962495
$443,114.06
in general payments reported to CMS, 2019-2025
21 companies · $136K in 2025
The $136K reported for 2025 was more than what 99% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $27K · 2020: $19K · 2021: $44K · 2022: $30K · 2023: $57K · 2024: $131K · 2025: $136K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $116K · Consulting Fee: $116K · Honoraria: $76K · Food and Beverage: $9,622 · Travel and Lodging: $7,197.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $115,617.28 |
| Consulting Fee | $115,556.50 |
| Honoraria | $75,981.00 |
| Food and Beverage | $9,622.38 |
| Travel and Lodging | $7,197.33 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Axsome Therapeutics, INC. | $193,175.16 | 2023-2025 | Auvelity |
| Alkermes, INC. | $128,357.10 | 2019-2025 | Lybalvi, Aristada, Aristada Initio |
| Otsuka America Pharmaceutical, INC. | $113,991.58 | 2019-2025 | Abilify Maintena, Abilify Asimtufii, Rexulti |
| Indivior INC. | $2,858.99 | 2019-2023 | Perseris |
| Brainsway USA INC | $2,150.43 | 2022 | |
| Janssen Pharmaceuticals, INC | $539.24 | 2019-2025 | Spravato, Invega Sustenna, Invega Trinza |
| Abbvie INC. | $523.44 | 2021-2025 | |
| Teva Pharmaceuticals USA, INC. | $244.35 | 2019-2023 | Uzedy |
| Lundbeck LLC | $243.20 | 2019-2025 | Abilify Maintena |
| Neurocrine Biosciences, INC. | $209.02 | 2020-2024 | Ingrezza |
| Allergan, INC. | $207.90 | 2019-2020 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $204.21 | 2022-2024 | Caplyta |
| Takeda Pharmaceuticals U.S.A., INC. | $98.89 | 2019-2022 | |
| Corium, LLC | $77.74 | 2024 | Azstarys |
| Avanir Pharmaceuticals, INC. | $56.05 | 2019-2022 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Acadia Pharmaceuticals INC | $47.50 | 2019 | |
| Vanda Pharmaceuticals INC. | $33.72 | 2020 | |
| Shire North American Group INC | $32.84 | 2019 | |
| Luye Pharma (USA) Ltd. | $29.54 | 2025 | Erzofri Extended-Release |
| Harmony Biosciences LLC | $19.85 | 2024 | |
| Idorsia Pharmaceuticals US INC | $13.31 | 2023 | Quviviq |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Joseph Fanelli listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.